文献速递物质与行为成瘾

注射用缓释纳曲酮与丁丙诺啡-纳洛酮日用方案治疗阿片依赖的随机非劣效试验

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

在挪威5个城市成瘾门诊开展12周开放标签随机非劣效试验,159名新近脱毒的阿片依赖成人随机接受每4周肌注缓释纳曲酮380 mg或每日口服丁丙诺啡-纳洛酮4–24 mg。缓释纳曲酮在试验完成率、阿片阴性尿检比例及海洛因和其他非法阿片使用天数上均非劣于丁丙诺啡-纳洛酮,且海洛因和其他非法阿片使用显著更少。

要点

  • 缓释纳曲酮在保持短期阿片戒断方面非劣于丁丙诺啡-纳洛酮。
  • 缓释纳曲酮组海洛因和其他非法阿片使用天数显著少于丁丙诺啡-纳洛酮组。
  • 缓释纳曲酮可作为阿片依赖患者的治疗选择。

核心结论

  • 缓释纳曲酮在维持海洛因及其他非法物质短期戒断方面与丁丙诺啡-纳洛酮同样有效,应被视为阿片依赖个体的治疗选择。

研究设计与样本

  • 共232名符合DSM-IV阿片依赖标准的成人被招募并评估资格,意向性治疗分析纳入所有随机参与者,最终159人随机分组,缓释纳曲酮组80人、丁丙诺啡-纳洛酮组79人。
  • 干预为每日口服 flexible dose 丁丙诺啡-纳洛酮4–24 mg/d,或每第4周肌注缓释纳曲酮380 mg,持续12周。

主要发现

  • 159名参与者平均(SD)年龄36(8.6)岁,44人(27.7%)为女性;105人(66.0%)完成试验。
  • 缓释纳曲酮组保留率非劣于丁丙诺啡-纳洛酮组(差异-0.1,95%CI -0.2至0.1,P=.04),平均(SD)时间分别为69.3(25.9)天和63.7(29.9)天(P=.33,log-rank检验)。
  • 缓释纳曲酮组在阿片阴性尿检总次数组比例上非劣于丁丙诺啡-纳洛酮组(均值[SD] 0.9[0.3] vs 0.8[0.4],差异0.1,95%CI -0.04至0.2,P<.001)。
  • 缓释纳曲酮组海洛因使用(均差-3.2,95%CI -4.9至-1.5,P<.001)和其他非法阿片使用(均差-2.7,95%CI -4.6至-0.9,P<.001)显著少于丁丙诺啡-纳洛酮组。
  • 两组在大多数其他非法物质使用上无显著差异。

关键数值与推荐

  • 主要终点为试验完成率、阿片阴性尿检比例及海洛因和其他非法阿片使用天数。
  • 缓释纳曲酮组试验完成率非劣于丁丙诺啡-纳洛酮组(差异-0.1,95%CI -0.2至0.1,P=.04)。
  • 缓释纳曲酮组阿片阴性尿检比例非劣于丁丙诺啡-纳洛酮组(差异0.1,95%CI -0.04至0.2,P<.001)。
  • 缓释纳曲酮组海洛因使用均差-3.2(95%CI -4.9至-1.5,P<.001),其他非法阿片使用均差-2.7(95%CI -4.6至-0.9,P<.001)。

临床怎么用

  • 对于新近脱毒的阿片依赖患者,可考虑每4周肌注缓释纳曲酮380 mg作为丁丙诺啡-纳洛酮的替代治疗选择。
  • 缓释纳曲酮在减少海洛因和其他非法阿片使用方面可能优于丁丙诺啡-纳洛酮,但需结合患者具体情况选择。

局限性

  • 开放标签设计可能影响主观报告结局。
  • 样本量159人,随访仅12周,长期效果未评估。
  • 研究在挪威城市成瘾门诊开展,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: To date, extended-release naltrexone hydrochloride has not previously been compared directly with opioid medication treatment (OMT), currently the most commonly prescribed treatment for opioid dependence. OBJECTIVE: To determine whether treatment with extended-release naltrexone will be as effective as daily buprenorphine hydrochloride with naloxone hydrochloride in maintaining abstinence from heroin and other illicit substances in newly detoxified individuals. DESIGN, SETTING AND PARTICIPANTS: A 12-week, multicenter, outpatient, open-label randomized clinical trial was conducted at 5 urban addiction clinics in Norway between November 1, 2012, and December 23, 2015; the last follow-up was performed on October 23, 2015. A total of 232 adult opioid-dependent (per DSM-IV criteria) individuals were recruited from outpatient addiction clinics and detoxification units and assessed for eligibility. Intention-to-treat analyses of efficacy end points were performed with all randomized participants. INTERVENTIONS: Randomization to either daily oral flexible dose buprenorphine-naloxone, 4 to 24 mg/d, or extended-release naltrexone hydrochloride, 380 mg, administered intramuscularly every fourth week for 12 weeks. MAIN OUTCOMES AND MEASURES: Primary end points (protocol) were the randomized clinical trial completion rate, the proportion of opioid-negative urine drug tests, and number of days of use of heroin and other illicit opioids. Secondary end points included number of days of use of other illicit substances. Safety was assessed by adverse event reporting. RESULTS: Of 159 participants, mean (SD) age was 36 (8.6) years and 44 (27.7%) were women. Eighty individuals were randomized to extended-release naltrexone and 79 to buprenorphine-naloxone; 105 (66.0%) completed the trial. Retention in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (difference, -0.1; with 95% CI, -0.2 to 0.1; P = .04), with mean (SD) time of 69.3 (25.9) and 63.7 (29.9) days, correspondingly (P = .33, log-rank test). Treatment with extended-release naltrexone showed noninferiority to buprenorphine-naloxone on group proportion of total number of opioid-negative urine drug tests (mean [SD], 0.9 [0.3] and 0.8 [0.4], respectively, difference, 0.1 with 95% CI, -0.04 to 0.2; P < .001) and use of heroin (mean difference, -3.2 with 95% CI, -4.9 to -1.5; P < .001) and other illicit opioids (mean difference, -2.7 with 95% CI, -4.6 to -0.9; P < .001). Superiority analysis showed significantly lower use of heroin and other illicit opioids in the extended-release naltrexone group. No significant differences were found between the treatment groups regarding most other illicit substance use. CONCLUSIONS AND RELEVANCE: Extended-release naltrexone was as effective as buprenorphine-naloxone in maintaining short-term abstinence from heroin and other illicit substances and should be considered as a treatment option for opioid-dependent individuals. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01717963.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry. 2017. PMID: 29049469. doi:10.1001/jamapsychiatry.2017.3206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。